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Inhibition of TGF-β expression: A 
novel role for thiazolidinediones 
to implement renoprotection in 
diabetes
N Perico1 and G Remuzzi1
Actual strategies to delay progression of diabetic nephropathy provide 
imperfect protection when started late in the course of the disease. 
Ohtomo et al. now demonstrate that thiazolidinedione treatment was 
associated with a remarkable improvement in proteinuria and renal 
function, offering a new potential treatment for diabetic nephropathy.
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Diabetes is rapidly emerging as a global 
health-care problem that threatens to reach 
pandemic levels by 2030. Indeed, the glo-
bal number of individuals with diabetes 
in 2000 was estimated to be 171 million, 
a ﬁgure projected to increase in 2030 to 
366 million, of whom 298 million will live 
in developing countries.1 Up to one-third 
of patients with diabetes develop diabetic 
nephropathy, which accounts for over 
40% of new cases of end-stage renal dis-
ease annually and is considered the lead-
ing cause of end-stage renal disease in the 
United States as well as Europe and Japan.
Among treatment options, agents that 
inhibit the renin–angiotensin system (RAS) 
are particularly eﬀective in reducing renal 
disease progression, owing to their actions 
on systemic and glomerular hypertension 
as well as to the unique property of this 
class of drugs of limiting protein ultraﬁl-
tration and its deleterious consequences.2 
The capacity of angiotensin-converting 
enzyme inhibitors (ACEi) to retard renal 
disease progression, however, depends on 
the time at which the treatment is started. 
Experimental data in streptozotocin-
induced diabetes indicate that ACEi given 
early after the induction of the disease sig-
niﬁcantly reduced systemic blood pressure 
and normalized urinary protein excretion.3 
By contrast, late administration of the drug 
was unable to aﬀect proteinuria, despite 
eﬀective control of blood pressure.3 Along 
the same lines, results of clinical trials have 
shown that RAS blockade largely prevented 
microalbuminuria4 and markedly limited 
progression to overt nephropathy in dia-
betic patients with incipient nephropathy5 
but led to less signiﬁcant reductions in the 
level of urinary protein excretion and in 
the rate of progression to end-stage renal 
failure, by only 25% and 20%, respectively, 
in type 2 diabetic patients with overt neph-
ropathy.6,7 It is therefore clear that agents 
that block angiotensin II provide imperfect 
renoprotection in diabetes, particularly 
in the advanced phase of the disease. An 
escalating number of publications sug-
gest that remission and regression of pro-
teinuric chronic nephropathies require a 
multimodel intervention, which should 
include—in addition to blood pressure 
control and proteinuria reduction—treat-
ment of dyslipidemia, control of metabolic 
abnormalities, and modiﬁcations of life-
style.8 Therefore, it is likely that a multidrug 
approach (along with exercise, banning of 
smoking, and body weight reduction) will 
represent the next improvement for diabetic 
patients with or without nephropathy.
Over the past several years, transforming 
growth factor-β (TGF-β) has been recog-
nized as a central player in the ﬁbrogenic 
process of diabetic nephropathy, via both 
stimulatory eﬀects on matrix production 
and blocking of matrix degradation.9 In 
several animal models of diabetes, TGF-β 
mRNA and protein levels are signiﬁcantly 
increased in the glomeruli and tubulointer-
stitium.9 Increased glomerular staining of 
TGF-β has also been described in patients 
with advanced diabetic nephropathy. Renal 
overexpression of this cytokine is attribut-
able to hyperglycemia, as is indicated by 
in vitro data showing that high ambient 
glucose fosters production of TGF-β by 
mesangial and tubular cells.9 The func-
tional role of TGF-β in vivo is emphasized 
by evidence that anti-TGF-β antibody 
given to db/db mice with a type 2 diabetes-
like disease almost completely prevented 
the increases in collagen and ﬁbronectin 
expression and mesangial matrix expan-
sion.10 Overall, these observations would 
provide the rationale for adding agents 
capable of reducing TGF-β activity or pro-
duction on top of inhibitors of angiotensin 
II activity, as one multimodal intervention 
to implement renoprotection in diabetic 
patients with overt nephropathy.
Evidence is available that components 
of the RAS and TGF-β interact, and they 
may do so in a very complex way in the 
kidney (Figure 1). Angiotensin II acts as a 
renal growth factor to induce hyperplasia/
hypertrophy of mesangial and tubular cells 
and stimulates the expression and synthesis 
of extracellular matrix proteins in intersti-
tial ﬁbroblasts. Some of these eﬀects seem 
to be mediated by the release of TGF-β 
and the upregulation of its receptors.11 
Furthermore, studies in animal models 
of chronic nephropathies have docu-
mented that RAS inhibitors signiﬁcantly 
blunted the increased renal TGF-β pro-
duction, which accounted at least partly 
for their renoprotective eﬀect.11 Likewise 
in patients with type 2 diabetes and neph-
ropathy, ACEi or dual blockade of RAS 
with ACEi and angiotensin II receptor 
blocker (ARB) reduced both renal TGF-
β gene expression and urinary excretion 
rate.12 Why, then, should we need to add 
inhibitors of TGF-β synthesis or activity 
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to an ACEi/ARB-based renoprotective 
treatment that is already considered the 
standard protocol for diabetic patients 
with or without nephropathy? A possible 
rationale for this approach rests on recent 
evidence that components of RAS other 
than angiotensin II additionally activate the 
TGF-β system.11 Indeed, renin increases 
mesangial-cell TGF-β expression and 
matrix proteins through a speciﬁc receptor, 
independently of angiotensin II. Similarly, 
angiotensin III enhances TGF-β mRNA 
expression in mesangial cells and in renal 
interstitial ﬁbroblasts. Moreover, aldoster-
one has been found to induce TGF-β pro-
tein by a post-transcriptional mechanism 
without inﬂuencing TGF-β transcripts. 
Thus, an integrated blockade of the intra-
renal RAS–TGF-β axis would be expected 
to reduce more effectively deleterious 
eﬀects of TGF-β on the kidney. Actually, 
the treatment with anti-TGF-β antibody, 
when added on the background of chronic 
angiotensin-converting enzyme inhibition, 
normalized proteinuria and abrogated 
glomerulosclerosis and tubular damage as 
compared with ACEi alone in diabetic rats 
with overt nephropathy.13
Despite encouraging results in diabetic 
animals with a multimodal intervention 
that includes anti-TGF-β antibody, the 
latter treatment is not so easily adaptable 
to diabetic patients. Anti-TGF-β antibod-
ies are just at the beginning of their clini-
cal development in proteinuric chronic 
nephropathies. Certainly more data are 
needed about their renoprotective eﬀects, 
in addition to the safety proﬁle, before they 
should be considered as an add-on to RAS 
inhibitors in diabetic patients.
A more clinically applicable approach 
to targeting TGF-β is now suggested by 
Ohtomo and co-workers in this issue of 
Kidney International.14 They examined 
the possible renoprotective properties 
of the thiazolidinedione pioglitazone as 
compared with those of insulin in the 
spontaneously hypertensive/NIH-cor-
pulent rat (SHR/NDmcr-cp), a model of 
type 2 diabetes with nephropathy. Despite 
reaching poorer glycemic control than 
insulin did, only pioglitazone prevented 
proteinuria and limited glomeruloscle-
rosis and tubulointerstitial ﬁbrosis. The 
drug’s action included both normalization 
of insulin levels and, more importantly, 
a marked reduction of intrarenal TGF-β 
mRNA expression. These ﬁndings extend 
to type 2 diabetes previous observations of 
antiproteinuric and renoprotective eﬀects 
of pioglitazone in rats with passive Heyman 
nephritis, a model of progressive nephropa-
thy, through transcriptional upregulation of 
the nephrin gene in podocytes.15 In strep-
tozotocin-induced experimental diabetes, 
pioglitazone suppressed the renal expres-
sion of TGF-β, reduced urinary albumin 
excretion, and ameliorated glomerular 
injury.16 In vitro, the ability of pioglitazone 
to decrease both excess TGF-β expression 
and apoptosis of podocytes upon toxic 
challenge further points to this cell type 
as a direct target for its protective eﬀects.17 
On the basis of these data, one may pre-
dict that pioglitazone could be a suitable 
option for add-on therapy to RAS block-
ade for renoprotection in diabetic patients. 
Indeed, besides lowering insulin resist-
ance and blood glucose level as do other 
thiazolidinediones that are already part of 
the standard treatment of type 2 diabetes, 
pioglitazone might provide additional ben-
eﬁts to patients with diabetic nephropathy 
by normalizing insulin level and by limit-
ing intrarenal TGF-β production. Pioglita-
zone is also likely to exert powerful eﬀects 
on mediators of injury that are targets of 
other members of this class of drugs but 
were not addressed in the study by Ohtomo 
et al.14 Among them, another report in this 
issue of Kidney International18 suggests that 
treatment with rosiglitazone reduces uri-
nary albumin excretion in patients with 
type 2 diabetes via inhibition of TNF-α 
and increase of adiponectin. On the other 
hand, preliminary data are already avail-
able in favor of combining an angiotensin 
II antagonist and pioglitazone to target 
proteinuria and to achieve better renopro-
tection, as compared with angiotensin II 
antagonist alone, in patients with type 2 
diabetic nephropathy.19
Although pioglitazone looks promising 
for the implementation of renoprotection 
in diabetic nephropathy, caution should 
be taken with thiazolidinedione medica-
tions, given the recent signal of concern of 
increase in the risk of myocardial infarc-
tion and, albeit non-signiﬁcant, in the risk 
of death from cardiovascular causes associ-
ated with the use of rosiglitazone in type 2 
diabetes.20 Given the pitfalls of the metaa-
nalysis that evaluated the cardiovascular 
outcomes in rosiglitazone-treated patients, 
the clinical impact of these data needs to 
be clariﬁed by more reliable information 
Figure 1 | Schematic representation of the interplay between the renin–angiotensin system 
(RAS) and TGF-β in the generation and progression of diabetic nephropathy. Ang, angiotensin.
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addressing the uncertainty about the 
safety of thiazolidinediones. Nevertheless, 
these observations underline the diﬃculty 
in determining the full safety proﬁle of a 
drug before its approval for marketing. 
Meanwhile, a United States federal advi-
sory panel said that rosiglitazone should 
remain on the market because its beneﬁts 
outweigh the risks, and studies concern-
ing the safety of the drug were too gloomy 
to impose drastic restriction to its market. 
Moreover, risks associated with rosiglita-
zone might be no worse than those of other 
diabetes medicines.  
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Genetic complexity in Joubert 
syndrome and related disorders
PC Harris1
The recent identification of RPGRIP1L as a Joubert syndrome gene brings 
the total of known genes to five. Three of these are also associated with 
the lethal Meckel syndrome, and two with Senior–Løken syndrome; both 
of these disorders share Joubert syndrome phenotypes, illustrating the 
genetic complexity of this.
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Joubert syndrome is an autosomal recessive 
disorder characterized by cerebellar ver-
mis hypoplasia, recognized by a distinctive 
brainstem malformation, the ‘molar tooth 
sign’ seen radiologically; abnormal eye 
movements; hypotonia; and development 
delay/mental retardation. Around a quar-
ter of patients also have nephronophthisis 
(NPHP, consisting of tubulointerstitial ﬁbro-
sis and cysts at the corticomedullary junc-
tion) and retinal dystrophy, which is termed 
Joubert syndrome type B, or cerebello-
oculo-renal syndrome (CORS). A number 
of other clinical abnormalities are found 
in Joubert syndrome and related disorders 
(JSRD), including occipital encephalocele, 
polymicrogyria, cystic kidneys, polydactyly, 
hepatic ﬁbrosis, and ocular coloboma. Sev-
eral of these phenotypes are similar to those 
associated with the lethal, recessive disorder 
Meckel syndrome (MKS), which is charac-
terized by renal cystic dysplasia, occipital 
encephalocele (or other central nervous 
system phenotypes), polydactyly, and 
hepatic ﬁbrosis. A group of related disor-
ders is recessively inherited isolated NPHP 
with an infantile, juvenile, or adolescent 
time at end-stage renal disease, which can 
also be associated with retinitis pigmentosa 
(Senior–Løken syndrome; SLS). Positional 
cloning studies in the past few years have 
revealed considerable genetic heterogeneity 
and genetic relatedness of these diseases.
Joubert syndrome has an approximately 
described incidence in the United States 
of 1 in 100,000, and five gene loci have 
been described: AHI1 (6q23.3),1 NPHP1 
(2q13),2 CEP290/NPHP6 (12q21.3),3 MKS3 
(8q22.1),4 and RPGRIP1L (16q12.2),5,6 
